Aligos Net Income Per E B T from 2010 to 2025

ALGS Stock  USD 16.87  0.11  0.66%   
Aligos Therapeutics Net Income Per E B T yearly trend continues to be comparatively stable with very little volatility. Net Income Per E B T will likely drop to 0.80 in 2025. From the period from 2010 to 2025, Aligos Therapeutics Net Income Per E B T quarterly data regression had r-value of (0.54) and coefficient of variation of  5.50. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
0.91
Current Value
0.8
Quarterly Volatility
0.05413695
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aligos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 960 K, Net Interest Income of 1.5 M or Interest Income of 1 M, as well as many indicators such as Price To Sales Ratio of 29.05, Dividend Yield of 0.0 or PTB Ratio of 4.24. Aligos financial statements analysis is a perfect complement when working with Aligos Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aligos Therapeutics Correlation against competitors.
For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Latest Aligos Therapeutics' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Aligos Therapeutics over the last few years. It is Aligos Therapeutics' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aligos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

Aligos Net Income Per E B T Regression Statistics

Arithmetic Mean0.98
Geometric Mean0.98
Coefficient Of Variation5.50
Mean Deviation0.03
Median1.00
Standard Deviation0.05
Sample Variance0
Range0.2092
R-Value(0.54)
Mean Square Error0
R-Squared0.29
Significance0.03
Slope(0.01)
Total Sum of Squares0.04

Aligos Net Income Per E B T History

2025 0.8
2024 0.91
2023 1.01

About Aligos Therapeutics Financial Statements

Aligos Therapeutics shareholders use historical fundamental indicators, such as Net Income Per E B T, to determine how well the company is positioned to perform in the future. Although Aligos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aligos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aligos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Income Per E B T 0.91  0.80 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.